Decentralised Clinical Trials in Low- and Middle-Income Settings: A Cross-Sectional Pilot Study of Feasibility and Readiness in Sri Lanka (DARWIN Project WP1)
Preprint
- 28 April 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Decentralised clinical trials (DCTs) have emerged as a transformative approach to improve accessibility, inclusivity, and efficiency in clinical research. However, evidence on their feasibility and implementation readiness in low- and middle-income countries remains limited. This study aimed to assess stakeholder awareness, perceptions, and system readiness for DCT implementation in Sri Lanka. Methods: A cross-sectional survey was conducted among 87 stakeholders, including academics, healthcare professionals, researchers, and regulatory personnel. Data were collected using a structured questionnaire assessing awareness, attitudes, perceived benefits and barriers, and readiness for DCT implementation. Descriptive statistics summarised responses, while bivariate analyses (chi-square and Fisher’s exact tests) and multivariable logistic regression were used to identify factors associated with perceived preparedness. Results: Awareness of DCTs was moderate (62.1%), and most participants recognised their potential to improve trial participation (88.5%). However, only 31.0% reported feeling adequately prepared to engage in DCTs. Institutional readiness was limited, with low availability of infrastructure (31.0%) and policies (16.1%). Regulatory familiarity (13.8%) and confidence in ethical guidance (10.3%) were also low. Key barriers included technological limitations (64.4%), data privacy concerns (58.6%), and patient safety issues (56.3%). Preparedness was significantly associated with prior training (p = 0.019) and institutional infrastructure (OR 3.31, 95% CI 1.21–9.09), but not with level of understanding. Conclusion: Stakeholders in Sri Lanka demonstrate strong conceptual support for DCTs but limited operational readiness. Implementation is constrained by system-level gaps rather than attitudinal barriers. Context-specific investment in infrastructure, training, and regulatory frameworks is essential to ensure equitable and sustainable adoption of decentralised clinical trials.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- Ethical Challenges and Considerations in Decentralized Clinical Trials (DCTs): Insights from a Scoping ReviewTherapeutic Innovation & Regulatory Science, 2026
- Selecting and Preparing Clinical Sites for the Successful Conduct of Decentralized Clinical Trial Activities–Findings From the Trials@Home RADIAL Proof‐of‐Concept TrialClinical Pharmacology & Therapeutics, 2025
- Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial EvidenceClinical Therapeutics, 2025
- Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of AccessJAMA Oncology, 2024
- Decentralisation in Clinical Trials and Patient Centricity: Benefits and ChallengesPharmaceutical Medicine, 2024
- Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment PerspectiveValue in Health, 2023
- Decentralised clinical trials: ethical opportunities and challengesThe Lancet Digital Health, 2023
- Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensusDrug Discovery Today, 2023
- The next generation of evidence-based medicineNature Medicine, 2023
- Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise themEuropean Journal of Internal Medicine, 2016